Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

OBJECTIVE: To evaluate apremilast treatment in patients with active psoriatic arthritis, including current skin involvement, despite prior therapy with conventional disease-modifying antirheumatic drugs and/or biologic agents. METHODS: Patients (N=505) were randomised (1:1:1) to placebo, apremilast...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Rheum Dis
Main Authors: Edwards, Christopher J, Blanco, Francisco J, Crowley, Jeffrey, Birbara, Charles A, Jaworski, Janusz, Aelion, Jacob, Stevens, Randall M, Vessey, Adele, Zhan, Xiaojiang, Bird, Paul
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2016
Assuntos:
Clinical and Epidemiological Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4893110/
https://ncbi.nlm.nih.gov/pubmed/26792812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2015-207963
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares